Correlation Between Incyte and Biomarin Pharmaceutical

Can any of the company-specific risk be diversified away by investing in both Incyte and Biomarin Pharmaceutical at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Incyte and Biomarin Pharmaceutical into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Incyte and Biomarin Pharmaceutical, you can compare the effects of market volatilities on Incyte and Biomarin Pharmaceutical and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Incyte with a short position of Biomarin Pharmaceutical. Check out your portfolio center. Please also check ongoing floating volatility patterns of Incyte and Biomarin Pharmaceutical.

Diversification Opportunities for Incyte and Biomarin Pharmaceutical

-0.44

Correlation Coefficient

Incyte  Biomarin Pharmaceutical

Very good diversification

The 3 months correlation between Incyte and Biomarin is -0.44. Overlapping area represents the amount of risk that can be diversified away by holding Incyte and Biomarin Pharmaceutical in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Biomarin Pharmaceutical and Incyte is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Incyte are associated (or correlated) with Biomarin Pharmaceutical. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Biomarin Pharmaceutical has no effect on the direction of Incyte i.e., Incyte and Biomarin Pharmaceutical go up and down completely randomly.

Pair Corralation between Incyte and Biomarin Pharmaceutical

Given the investment horizon of 90 days Incyte is expected to generate 1.4 times more return on investment than Biomarin Pharmaceutical. However, Incyte is 1.4 times more volatile than Biomarin Pharmaceutical. It trades about 0.18 of its potential returns per unit of risk. Biomarin Pharmaceutical is currently generating about 0.0 per unit of risk. If you would invest  5,961  in Incyte on May 6, 2025 and sell it today you would earn a total of  1,603  from holding Incyte or generate 26.89% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Incyte  vs.  Biomarin Pharmaceutical

Incyte

Risk-Adjusted Performance

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Incyte are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating fundamental indicators, Incyte showed solid returns over the last few months and may actually be approaching a breakup point.

Biomarin Pharmaceutical

Risk-Adjusted Performance

Very Weak

Over the last 90 days Biomarin Pharmaceutical has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, Biomarin Pharmaceutical is not utilizing all of its potentials. The current stock price disarray, may contribute to short-term losses for the investors.

Pair Trading with Incyte and Biomarin Pharmaceutical

The main advantage of trading using opposite Incyte and Biomarin Pharmaceutical positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Incyte position performs unexpectedly, Biomarin Pharmaceutical can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biomarin Pharmaceutical will offset losses from the drop in Biomarin Pharmaceutical's long position.

The idea behind Incyte and Biomarin Pharmaceutical pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.